ALNY: Leadership change · Other company developments

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On November 4, 2026, Alnylam Pharmaceuticals, Inc. (the “Company”) announced that Tolga Tanguler will depart from his role as the Company’s Executive Vice President, Chief Commercialization Officer in December 2026. Mr. Tanguler and the Company intend to enter into a written agreement not later than his separation date, which will contain the terms of his departure from the Company. Item 8.01. Other Events On November 2, 2026, the Board of Directors of the Company authorized a program to repurchase up to $1.0 billion of the Company’s common stock (the “2026 Repurchase Program”). Repurchases under the 2026 Repurchase Program may be made from time to time in open market transactions, including pursuant to trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in privately negotiated transactions, or by other means, in each case in accordance with applicable securities laws, including Rule 10b-18 under the Exchange Act. The Company anticipates repurchasing approximately $500 million of its common stock authorized under the 2026 Repurchase Program by the end of 2026 and the balance during 2027, but the timing and amount of any repurchases will depend on a number of factors, including the market price of the Company’s common stock, general business and market conditions, the Company’s liquidity and capital requirements and other investment opportunities. The 2026 Repurchase Program does not have an expiration date, does not obligate the Company to repurchase any particular dollar amount or number of shares, and may be modified, suspended or disc